Digest Network Come funziona
Network
/
Società
Da
Non verificato

Daiichi Sankyo

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VarieOncologiaSalute

72 comunicati stampa

Guarda tutti i comunicati
03/12/2025
Legge/Diritto
Oncologia
Salute
Sanità
Farmaceutica
Cardiologia
Biotecnologia
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
10/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Industria
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
31/10/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
19/10/2025
Eventi
Fiere
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
19/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
19/10/2025
Eventi
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
18/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
18/10/2025
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
17/10/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Eventi
Industria
DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
13/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Telefonia e Varie
Industria
Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0